In a clinical trial, participants lost an average of 5.1% of their body weight in 72 weeks, suggesting Oroforglipron may be more effective for weight management than Rybelsus
Validation frameworks that require NAMs to outperform animal data need to account for what that data actually looks like in practice, not what we assume it looks like
Occasionally, appetite decreases more than anticipated initially and that can shift the way an individual thinks about food, eating, and control, which can contribute to stress or anxiety
If appetite regulation, fat loss, and metabolic improvement are occurring without excessive side effects, a slower titration may be clinically reasonable
(2025, Nature Metabolism ) reported daLUXendin and daLUXendin+, non-lipidated and lipidated dual GLP-1/GIP receptor agonist fluorescent probes with nanomolar affinity at both hGLP1R and hGIPR
But the company sells GLP-1 drugs like Ozempic and Wegovy, which according to a 2024 poll, are being used by roughly 6 percent of Americans (thats an estimated 20 million people)
